Faron Pharmaceuticals Oy (AIM:FARN)
London flag London · Delayed Price · Currency is GBP · Price in GBX
53.65
-4.35 (-7.50%)
Mar 5, 2026, 8:42 AM GMT

Faron Pharmaceuticals Oy Balance Sheet

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
12.329.56.886.996.85
Cash & Short-Term Investments
12.329.56.886.996.85
Cash Growth
29.61%38.22%-1.65%2.00%66.82%
Other Receivables
-0.280.230.911.42
Receivables
-0.280.230.911.42
Prepaid Expenses
3.511.281.761.843.75
Other Current Assets
--00--
Total Current Assets
15.8311.078.879.7312.02
Property, Plant & Equipment
0.190.30.20.330.21
Other Intangible Assets
1.121.111.091.150.9
Other Long-Term Assets
0.040.050.060.060.05
Total Assets
17.1712.5210.2211.2713.18
Accounts Payable
5.554.888.976.012.23
Accrued Expenses
2.931.462.42.454.06
Current Portion of Long-Term Debt
10.273.723.481.850.43
Current Portion of Leases
0.130.120.160.150.18
Other Current Liabilities
----0.28
Total Current Liabilities
18.8710.1715.0110.477.18
Long-Term Debt
14.28.099.4211.12.92
Long-Term Leases
0.080.190.050.160.02
Other Long-Term Liabilities
2.533.840.91.010.15
Total Liabilities
35.6822.2825.3822.7510.26
Common Stock
2.692.692.692.692.69
Retained Earnings
-222.86-197.42-172.21-143.71-116.27
Comprehensive Income & Other
201.66184.97154.36129.55116.49
Shareholders' Equity
-18.51-9.76-15.16-11.482.92
Total Liabilities & Equity
17.1712.5210.2211.2713.18
Total Debt
24.6812.1113.1113.273.55
Net Cash (Debt)
-12.36-2.61-6.24-6.283.31
Net Cash Growth
----274.41%
Net Cash Per Share
-0.11-0.03-0.10-0.110.07
Filing Date Shares Outstanding
119.74104.6268.7959.8153.23
Total Common Shares Outstanding
119.74104.6268.7959.8153.23
Working Capital
-3.050.89-6.14-0.744.85
Book Value Per Share
-0.15-0.09-0.22-0.190.05
Tangible Book Value
-19.62-10.87-16.25-12.632.02
Tangible Book Value Per Share
-0.16-0.10-0.24-0.210.04
Machinery
-0.030.030.060.06
Source: S&P Global Market Intelligence. Standard template. Financial Sources.